May 6th 2024
Although chronic respiratory diseases remain the third leading cause of mortality, they have received less attention from the global community.
Medical Crossfire®: How Can Thoracic Teams Facilitate Optimized Care of Patients With Stage I-III EGFR Mutation-Positive NSCLC?
May 21, 2024
Register Now!
19th Annual New York Lung Cancers Symposium®
November 16, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Identifying Actionable Biomarkers in NSCLC: Real World Case Discussions on Applications of Testing in the Treatment Planning Process
View More
Improving Outcomes Across Frontline and R/R SCLC Care in Community Treatment Settings
View More
It's Time to Rethink Respiratory Virus Transmission and How To Prevent It in Healthcare Settings
November 24th 2021The traditional dividing line between transmission by droplets and smaller aerosols is incorrect, say the authors of a Annals of Internal Medicine review paper, and infection control measures need to reflect the new understanding that respiratory viruses spread in respiratory particles of all sizes and perhaps mainly in aerosols.
Read More
The Effects of Classroom Air Purifiers, Pest Management on Students with Active Asthma
September 24th 2021In a study conducted by JAMA, results were recently released sharing children with active asthma had reduced symptom days, but not significantly, in the use of a school-wide integrated pest management program or a high-efficiency particulate air filter purifier in recorded 2-week time periods.
Read More
Renovion, COPD Foundation Launch Partnership to Address Unmet Needs for COPD Patients
September 23rd 2021Efforts are underway to accelerate the development of a novel therapy for excessive airway mucus and inflammation treatment for patients with chronic obstructive pulmonary disease and non-cystic fibrosis bronchiectasis.
Read More
5 Takeaways About Pulmonary Rehabilitation
September 23rd 2021Three experts say that pulmonary rehabilitation programs don’t necessarily result in improved lung function but are associated with improved physical and other sorts of functioning. Less than 5% of those who might benefit from pulmonary rehabilitation services received them.
Read More
ICER Foresees AstraZeneca’s Tezepelumab for Severe Asthma As Being Only Modestly Cost Effective
September 17th 2021Tezepelumab, which is being currently reviewed by the FDA, provides small improvements in daily symptoms and quality of life but is only modestly cost-effectiveness at the anticipated price, according to the cost-effectiveness group's calculations.
Read More
FDA Roundup: Pediatric Indications, More in Alzheimer's Pipeline?
June 26th 2021Regulatory actions for drugs for children, a combination cancer therapy, launches of two generic therapies for COPD, and cancer and Alzheimer’s therapies receive Breakthrough Designation round out this week’s FDA news.
Read More
The pharmacologic management of pulmonary arterial hypertension
May 1st 2007Pulmonary arterial hypertension (PAH) is a disease state characterized by vascular narrowing and increased pulmonary vascular resistance. Physical symptoms, which may include fatigue or weakness, exertional dyspnea, and peripheral edema, are often nonspecific and can mimic more common disorders encountered in clinical practice. Healthcare professionals have been limited in which medications could be used to treat this condition because clinical data have been scarce. Recently, multiple new classes of medications, many of which are very costly, have become available; these agents offer physicians more therapeutic options for the treatment of PAH. Managed-care organizations have been challenged with suggesting the appropriate place in therapy for these new agents, as well as ensuring their safe and cost-effective utilization. This review summarizes the data available for the drugs used to treat PAH, with the goal of helping organizations to make appropriate decisions regarding the proper use of these agents.
Read More
Arformoterol: The first nebulized long-acting beta2-adrenergic agonist
February 1st 2007Bronchodilators play an important role in the management of stable chronic obstructive pulmonary disease (COPD). Although bronchodilators do not prevent the decline in lung function in patients with COPD, their efficacy in improving disease-related symptoms, reducing the frequency and severity of disease exacerbations, and improving patients' quality of life has been demonstrated in clinical trials. Arformoterol, the (R,R)-enantiomer of the selective beta2-agonist formoterol, is a potent, highly specific, nebulized long-acting beta2-adrenergic agonist recently approved by FDA for the long-term maintenance treatment of bronchoconstriction in patients with COPD, including chronic bronchitis and emphysema. In 2 large, 12-week, phase 3 studies, arformoterol demonstrated an efficacy superior to that of placebo and comparable to that of salmeterol in patients with COPD. In these trials, arformoterol was well tolerated, with a safety profile similar to that of other inhaled long-acting beta2-agonists when used at..
Read More
This selective long-acting beta2-adrenergic receptor agonist causes relaxation of bronchial smooth muscle and has 2-fold greater potency than racemic formoterol. Arformoterol was approved on October 6, 2006, for the long-term, twice-daily (morning and evening) maintenance treatment of bronchoconstriction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.
Read More
Administration of inhaled corticosteroids (ICS) within 90 days of hospital discharge is effective in reducing mortality in chronic obstructive pulmonary disease (COPD) patients, especially among those aged 35 to 64 years, according to a recent study published in the journal Chest.
Read More